Literature DB >> 29185395

PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.

Asad Javed1, David Arguello2, Curtis Johnston2, Zoran Gatalica2, Mizue Terai1, Ryan M Weight1, Marlana Orloff1, Michael J Mastrangelo1, Takami Sato1.   

Abstract

AIM: To compare PD-L1 expression between metastatic uveal melanoma (MUM) and metastatic cutaneous melanoma (MCM). MATERIALS &
METHODS: A total of 295 MCM and 78 MUM specimens were analyzed for tumor cell PD-L1 expression. Additionally, 91 MCM and 45 MUM specimens were analyzed for PD-1 expression on tumor-infiltrating lymphocytes.
RESULTS: A total of 77/295 (26.1%) MCM specimens expressed PD-L1 as compared to 4/78 (5.1%) MUM specimens (p < 0.0001). PD-1 expression on tumor-infiltrating lymphocytes was greater in MCM (73.6%; 67/91) than in MUM (51.1%; 23/45), respectively (p = 0.009).
CONCLUSION: Significant differences exist in PD-L1 expression between MCM and MUM. The lower PD-L1 expression in MUM may provide a rationale for failure of PD-1 inhibitor therapy and suggests that immune evasion in this disease may occur via alternative mechanisms.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29185395     DOI: 10.2217/imt-2017-0066

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  19 in total

Review 1.  Immunotherapy of Melanoma: Facts and Hopes.

Authors:  Sarah A Weiss; Jedd D Wolchok; Mario Sznol
Journal:  Clin Cancer Res       Date:  2019-03-28       Impact factor: 12.531

2.  A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases.

Authors:  Surein Arulananda; Sagun Parakh; Jodie Palmer; Mark Goodwin; Miles C Andrews; Jonathan Cebon
Journal:  Cancer Rep (Hoboken)       Date:  2019-05-14

3.  Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.

Authors:  Richard D Carvajal; Marcus O Butler; Alexander N Shoushtari; Jessica C Hassel; Alexandra Ikeguchi; Leonel Hernandez-Aya; Paul Nathan; Omid Hamid; Josep M Piulats; Matthew Rioth; Douglas B Johnson; Jason J Luke; Enrique Espinosa; Serge Leyvraz; Laura Collins; Howard M Goodall; Koustubh Ranade; Chris Holland; Shaad E Abdullah; Joseph J Sacco; Takami Sato
Journal:  Nat Med       Date:  2022-10-13       Impact factor: 87.241

Review 4.  Clinicopathological and prognostic significance and molecular mechanisms governing uveal melanoma.

Authors:  Meng-Yu Wu; Tzu-Ting Lai; Wan-Ting Liao; Chia-Jung Li
Journal:  Ther Adv Med Oncol       Date:  2020-06-08       Impact factor: 8.168

5.  Interferon Signaling Is Frequently Downregulated in Melanoma.

Authors:  Sara Alavi; Ashleigh Jacqueline Stewart; Richard F Kefford; Su Yin Lim; Elena Shklovskaya; Helen Rizos
Journal:  Front Immunol       Date:  2018-06-21       Impact factor: 7.561

6.  Pembrolizumab as first-line treatment for metastatic uveal melanoma.

Authors:  Ernesto Rossi; Monica Maria Pagliara; Daniela Orteschi; Tommaso Dosa; Maria Grazia Sammarco; Carmela Grazia Caputo; Gianluigi Petrone; Guido Rindi; Marcella Zollino; Maria Antonietta Blasi; Alessandra Cassano; Emilio Bria; Giampaolo Tortora; Giovanni Schinzari
Journal:  Cancer Immunol Immunother       Date:  2019-06-07       Impact factor: 6.968

7.  Expression of immune checkpoint receptors Indoleamine 2,3-dioxygenase and T cell Ig and ITIM domain in metastatic versus nonmetastatic choroidal melanoma.

Authors:  Gustav Stålhammar; Stefan Seregard; Hans E Grossniklaus
Journal:  Cancer Med       Date:  2019-04-16       Impact factor: 4.452

8.  Differential modulation and prognostic values of immune-escape genes in uveal melanoma.

Authors:  Maria Sofia Basile; Emanuela Mazzon; Andrea Russo; Santa Mammana; Antonio Longo; Vincenza Bonfiglio; Matteo Fallico; Rosario Caltabiano; Paolo Fagone; Ferdinando Nicoletti; Teresio Avitabile; Michele Reibaldi
Journal:  PLoS One       Date:  2019-01-17       Impact factor: 3.240

Review 9.  The Role of Immune Checkpoint Blockade in Uveal Melanoma.

Authors:  Anja Wessely; Theresa Steeb; Michael Erdmann; Lucie Heinzerling; Julio Vera; Max Schlaak; Carola Berking; Markus Vincent Heppt
Journal:  Int J Mol Sci       Date:  2020-01-29       Impact factor: 5.923

10.  CD8 Positive T Lymphocyte Infiltration of Liver Metastases of Uveal Melanoma: A Case Report.

Authors:  Naoki Takahashi; Kazuto Tajiri; Ko Kagoyana; Shinichi Tanaka; Ichiro Yasuda
Journal:  Front Oncol       Date:  2021-06-02       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.